AbbVie Seeks EMA Nod For SKYRIZI Subcutaneous Induction In Crohn's Disease
AbbVie (ABBV) submitted a regulatory application to the European Medicines Agency for SKYRIZI subcutaneous induction in Crohn's disease. The application is based on positive Phase 3 AFFIRM study results, showing clinical remission and endoscopic response at week 12. If approved, patients could choose between SC injection or IV infusion for induction, followed by SC maintenance dosing. SKYRIZI is already approved for Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
How this was made
The 30-second read
Why it matters
If approved, the new route could increase patient adherence and market share, positively impacting AbbVie's earnings outlook.
Market read
Regulatory progress for a major drug can move the stock and influence sector sentiment.
What to watch
Potential competition from biosimilars and pricing negotiations in Europe.
Background
AbbVie’s SKYRIZI is already approved for IV induction and maintenance; this filing seeks a subcutaneous induction option for Crohn's disease.
Ticker impact
AbbVie submitted an EMA application for subcutaneous SKYRIZI induction in Crohn's disease.
Short-term upside if EMA nod is granted; price may rise on approval news.
Regulatory filing for a new administration route is a material catalyst for a large-cap biotech.
Market effects
May encourage other biotech firms to pursue subcutaneous formulations for biologics.
European markets could see increased interest in AbbVie shares ahead of EMA decision.
Adds to broader trend of expanding biologic delivery options worldwide.
Counterpoint
Approval risk remains; EMA could request additional data, delaying launch.
Key entities
- CompanyAbbVie
Pharmaceutical company developing SKYRIZI.
- Regulatory AgencyEMA
European Medicines Agency reviewing the application.
